| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Unit of Cell and Molecular Biology, The Dental School, University of Dundee, Dundee, Scotland;
2 Masaryk Memorial Cancer Institute, Brno, Czech Republic; and Departments of
3 Molecular and Cellular Pathology and
4 Cytogenetics, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland
Migration-stimulating factor (MSF) is a 70-kDa motogenic protein previously reported to be expressed by fetal and cancer patient fibroblasts cultured in vitro and present in the serum of breast cancer patients. A 2.2-kb full-length MSF cDNA has been cloned and shown to be a truncated isoform of fibronectin generated from its primary gene transcript by a hitherto unrecognized intron read-through mechanism. MSF cDNA is identical to the 5' end of fibronectin cDNA, up to and including exon III-1a, and terminates in a novel 195-nucleotide 3' sequence. This MSF unique sequence is derived from the intron immediately downstream of exon III-1a in the fibronectin gene and is not found in any previously identified "full-length" fibronectin cDNA. MSF mRNA is 1000-fold less abundant than full-length fibronectin message in fetal fibroblasts and exhibits rapid biphasic decay kinetics previously associated with oncogenes and stress response molecules. MSF recombinant protein exhibits a potent and substratum-dependent motogenic activity, with half-maximal response manifest at 0.1–1.0 pg/ml. This activity is (a) mediated by the IGD amino acid motif; and (b) not expressed by (i.e., cryptic within) full-length fibronectin. In situ hybridization and immunohistochemistry confirm that MSF is expressed by tumor-associated fibroblasts and additionally indicate that it is also expressed by carcinoma cells and tumor-associated vascular endothelial cells. MSF, as a consequence of its potent bioactivities and expression by both stromal and carcinoma cell populations, is well placed to function as an epigenetic effector promoting cancer development.
This article has been cited by other articles:
|
|
 |
|
  K. J. Hamill, L. Langbein, J. C. R. Jones, and W. H. I. McLean Identification of a Novel Family of Laminin N-terminal Alternate Splice Isoforms: STRUCTURAL AND FUNCTIONAL CHARACTERIZATION J. Biol. Chem., December 18, 2009; 284(51): 35588 - 35596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Vakonakis, D. Staunton, I. R. Ellis, P. Sarkies, A. Flanagan, A. M. Schor, S. L. Schor, and I. D. Campbell Motogenic Sites in Human Fibronectin Are Masked by Long Range Interactions J. Biol. Chem., June 5, 2009; 284(23): 15668 - 15675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hu, Y. Ran, Y. Zhang, Z. Zhou, S. J. Harris, L. Yu, L. Sun, J. Pan, J. Liu, J. Lou, et al. Antibody Library-based Tumor Endothelial Cells Surface Proteomic Functional Screen Reveals Migration-stimulating Factor as an Anti-angiogenic Target Mol. Cell. Proteomics, April 1, 2009; 8(4): 816 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Eyden, S S Banerjee, P Shenjere, and C Fisher The myofibroblast and its tumours J. Clin. Pathol., March 1, 2009; 62(3): 236 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ambesi and P. J. McKeown-Longo Anastellin, the Angiostatic Fibronectin Peptide, Is a Selective Inhibitor of Lysophospholipid Signaling Mol. Cancer Res., February 1, 2009; 7(2): 255 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wels, R. N. Kaplan, S. Rafii, and D. Lyden Migratory neighbors and distant invaders: tumor-associated niche cells Genes & Dev., March 1, 2008; 22(5): 559 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Millard, I. R. Ellis, A. R. Pickford, A. M. Schor, S. L. Schor, and I. D. Campbell The Role of the Fibronectin IGD Motif in Stimulating Fibroblast Migration J. Biol. Chem., December 7, 2007; 282(49): 35530 - 35535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Tomkowicz, K. Rybinski, B. Foley, W. Ebel, B. Kline, E. Routhier, P. Sass, N. C. Nicolaides, L. Grasso, and Y. Zhou Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration PNAS, November 13, 2007; 104(46): 17965 - 17970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sandal, K. Valyi-Nagy, V. A. Spencer, R. Folberg, M. J. Bissell, and A. J. Maniotis Epigenetic Reversion of Breast Carcinoma Phenotype Is Accompanied by Changes in DNA Sequestration as Measured by AluI Restriction Enzyme Am. J. Pathol., May 1, 2007; 170(5): 1739 - 1749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Kay, I. R. Ellis, S. J. Jones, S. Perrier, M. M. Florence, A. M. Schor, and S. L. Schor The Expression of Migration Stimulating Factor, a Potent Oncofetal Cytokine, Is Uniquely Controlled by 3'-Untranslated Region-Dependent Nuclear Sequestration of Its Precursor Messenger RNA Cancer Res., December 1, 2005; 65(23): 10742 - 10749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Amatangelo, D. E. Bassi, A. J.P. Klein-Szanto, and E. Cukierman Stroma-Derived Three-Dimensional Matrices Are Necessary and Sufficient to Promote Desmoplastic Differentiation of Normal Fibroblasts Am. J. Pathol., August 1, 2005; 167(2): 475 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.J. BISSELL, P.A. KENNY, and D.C. RADISKY Microenvironmental Regulators of Tissue Structure and Function Also Regulate Tumor Induction and Progression: The Role of Extracellular Matrix and Its Degrading Enzymes Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 343 - 356. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
